30 closest matches · ranked by relevance
Contraception
Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
Insulin Sensitivity · Cardiovascular Risk · Perimenopausal Disorder
Primary: Change From Baseline in Insulin Sensitivity — -1.91; -5.63 min ^ -1 / mIU / L
Contraception
Primary: Continuation Rates — 82; 78; 83 participants
Abortion
Primary: Number of Participants Who Use Patch After Abortion, by Study Arm — 36; 42 Participants
Contraception
Primary: Interest BC4Teens Care — 231 Participants
Contraception · Unintended Pregnancy
Primary: Unintended Pregnancy — 46; 25 Participants
Contraception
Primary: Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy — 2.44; 2.42; 1.77…
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
Contraception
Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) — 82.1; 81.9 Percentage of participants
Contraceptive Usage · Overweight or Obesity · Body Weight Changes
Primary: Number of Premenopausal Women With Overweight/Obesity Who Initiated a COC vs. Continued NHC Use, Enrolled and Remained in This Study, and Completed Outcome Measures — 9…
Contraception · Contraceptive Behavior
Primary: Contraceptive Continuation — 201; 174; 154; 118 Participants — p=0.46
Contraception
Primary: Shared Decision-making About Contraceptive Methods — 165; 272; 222; 190 Participants — p=0.80
Contraception Behavior
Primary: Number of Participants With Implant Continuation — 219; 225 Participants
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
Dysmenorrhea
Primary: Change in Visual Analog Scale (VAS) Score — -74.8; -58.7 units on a scale — p=0.05
Oral Contraceptive
Primary: Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups — 7.5; 12.4 Percent of cells staining for Ki67
Contraception
Primary: Number of Participants Using an Effective Contraceptive Method 6 Weeks After Abortion — 55; 55 Participants
Prevention of Pregnancy
Primary: Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population — 1.823; 2.978 Pearl Index
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Breakthrough Bleeding
Primary: Endometrial Matrix Metalloproteinase Expression by Gel Densitometry — 1.33; 2.49 relative expression
Body Weight · Contraceptive Usage
Primary: LNG Steady State at Baseline and Then Post-randomization — 3.82; 3.13; 3.01; 3.58 ng/mL
Oral Contraceptive
Primary: Breast Cell Proliferation Levels Between the Three Oral Contraceptive Groups — 8.5; 11.9; 7.5 Percent of cells staining for Ki67
Contraception · Decision Making · Satisfaction
Primary: Decisional Conflict Scale Score — 15; 10; 0; 0 score on a scale
Contraception
Primary: Number of Participants With Depot Medroxyprogesterone Acetate (DMPA sc) Continuation at One Year by Self-report in Both the Self- and Clinic Administration Arms — 108…
Birth Control Compliance
Primary: Adherence Rate (Rate of Perfect Method Use) — 57; 45 Percentage of Participants — p=0.05
Healthy
Primary: Cmax of Norethindrone — 4.3306; 4.2282 ng/mL